Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation.
Famularo, Giuseppe, De Simone, Claudio, Trinchieri, Vito et al. · Annals of the New York Academy of Sciences · 2004 · DOI
Quick Summary
This review discusses carnitine, a natural substance in the body that helps cells produce energy from fats. Carnitine levels are low in several conditions involving immune problems, including ME/CFS. The authors suggest that low carnitine may contribute to immune dysfunction and excessive inflammation, and that carnitine treatment might help restore normal immune function.
Why It Matters
This work identifies a potential metabolic mechanism underlying immune dysregulation in ME/CFS, suggesting that carnitine deficiency may contribute to the disease pathophysiology. If carnitine metabolism is truly impaired in ME/CFS patients, this could open avenues for therapeutic intervention and metabolic testing, addressing a significant gap in understanding how cellular energy production relates to immune dysfunction.
Observed Findings
Reduced carnitine pools detected in serum and/or tissues of patients with multiple immune-dysregulating disorders including ME/CFS
Carnitine-dependent fatty acid oxidation appears essential for normal immune cell function
Carnitine treatment modulated impaired immune responses in experimental models of aging and infection
Carnitine deficiency associated with worse outcomes in sepsis models and endotoxin-mediated organ failure
Carnitine therapy in HIV patients reduced lymphocyte apoptosis and improved CD4 counts in preliminary studies
Inferred Conclusions
Carnitine deficiency is a contributing factor in the pathophysiology of multiple immune-dysregulated conditions, including ME/CFS
Carnitine supplementation may partially restore or modulate impaired immune responses and excessive inflammation
Carnitine's role in immune regulation is primarily mediated through its function in fatty acid-dependent energy production
Carnitine therapy warrants further investigation as a potential therapeutic approach for carnitine-deficient immune disorders
Remaining Questions
Is carnitine deficiency primary (a causative factor) or secondary (a consequence of disease) in ME/CFS?
What This Study Does Not Prove
This review does not establish causation—it identifies an association between low carnitine and immune dysfunction, but does not prove carnitine deficiency causes ME/CFS. The mechanistic evidence is drawn primarily from experimental models and other conditions; clinical efficacy of carnitine treatment specifically in ME/CFS is not demonstrated here. The review does not account for whether low carnitine is a primary defect or a secondary consequence of disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →